CL2009001159A1 - Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon. - Google Patents

Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon.

Info

Publication number
CL2009001159A1
CL2009001159A1 CL2009001159A CL2009001159A CL2009001159A1 CL 2009001159 A1 CL2009001159 A1 CL 2009001159A1 CL 2009001159 A CL2009001159 A CL 2009001159A CL 2009001159 A CL2009001159 A CL 2009001159A CL 2009001159 A1 CL2009001159 A1 CL 2009001159A1
Authority
CL
Chile
Prior art keywords
difumarate
oxy
chloro
methylcarbamoylmethyl
fluoroanilino
Prior art date
Application number
CL2009001159A
Other languages
English (en)
Inventor
Andrew Hornby Dobson
Susan Elizabeth Burns
Brian Whitlock
Kay Alison Boardman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40935682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001159(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2009001159A1 publication Critical patent/CL2009001159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

DIFUMARATO DE 4-(3-CLORO-2-FLUOROANILINO)-7-METOXI-6-{[1-(N-METILCARBOMOILMETIPIPERIDIN-4- IL]OXI}QUINAZOLINA; FORMA CRISTALINA A DEL DIFUMARATO; PROCESOS DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA; Y EL USO DEL DIFUMARATO EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS COMO EL CÁNCER.
CL2009001159A 2008-05-13 2009-05-13 Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon. CL2009001159A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5270608P 2008-05-13 2008-05-13
US11063708P 2008-11-03 2008-11-03

Publications (1)

Publication Number Publication Date
CL2009001159A1 true CL2009001159A1 (es) 2010-06-11

Family

ID=40935682

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001159A CL2009001159A1 (es) 2008-05-13 2009-05-13 Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon.

Country Status (31)

Country Link
US (2) US8088782B2 (es)
EP (1) EP2303276B1 (es)
JP (1) JP5739802B2 (es)
KR (1) KR20110014192A (es)
CN (1) CN102088979B (es)
AR (1) AR071714A1 (es)
AU (1) AU2009247782C1 (es)
BR (1) BRPI0912170A2 (es)
CA (1) CA2723989C (es)
CL (1) CL2009001159A1 (es)
CO (1) CO6321256A2 (es)
CR (1) CR11791A (es)
CU (1) CU23927B1 (es)
DO (1) DOP2010000346A (es)
EA (1) EA019183B1 (es)
EC (1) ECSP10010610A (es)
ES (1) ES2444128T3 (es)
HK (1) HK1152867A1 (es)
HN (1) HN2010002408A (es)
IL (1) IL209199A0 (es)
MX (1) MX2010012442A (es)
MY (1) MY183041A (es)
NI (1) NI201000197A (es)
NZ (1) NZ589883A (es)
PE (1) PE20091970A1 (es)
SA (1) SA109300290B1 (es)
SV (1) SV2010003734A (es)
TW (1) TWI443095B (es)
UY (1) UY31820A (es)
WO (1) WO2009138781A1 (es)
ZA (1) ZA201008283B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
BRPI1013854A2 (pt) * 2009-04-23 2017-05-16 Astrazeneca Ab processo para a preparação de composto, composto, e, sal de um composto
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
JP6769962B2 (ja) * 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド 癌治療のためのキナーゼ阻害剤プロドラッグ
US20240025874A1 (en) * 2018-04-08 2024-01-25 Wayshire Biopharm Holding Limited Quinazoline Derivative Salt Crystal Form, Preparation Method and Application
CN109384747A (zh) * 2018-10-26 2019-02-26 苏州立新制药有限公司 吉非替尼相关物质及其制备和检测方法
WO2022170052A1 (en) * 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4332420A (en) 1980-01-11 1982-06-01 Coski William D Reciprocably supported dual drive member and features thereof
US4456359A (en) 1981-11-04 1984-06-26 Ciba-Geigy Ag Flat photographic sheet processing cassette
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (de) 1991-02-19 1992-08-20 Jenapharm Gmbh Ausgangsverbindungen zur herstellung von calcitriol sowie dessen abkoemmlingen, verfahren zur herstellung dieser ausgangsverbindungen sowie zwischenprodukte fuer dieses verfahren
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69203164T2 (de) * 1991-06-04 1995-11-02 Fujisawa Pharmaceutical Co Vorbeugende/therapeutische Zusammensetzung für die Pleuropneumonie des Schweins.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
ATE171446T1 (de) 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ATE298566T1 (de) 1995-09-11 2005-07-15 Osteoarthritis Sciences Inc Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9702049B1 (pt) * 1996-01-31 2010-08-10 sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas.
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9626589D0 (en) * 1996-12-20 1997-02-05 Prolifix Ltd Peptides
CA2282439C (en) 1997-03-05 2010-05-04 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ATE241986T1 (de) 1997-05-06 2003-06-15 Wyeth Corp Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
ATE309225T1 (de) 1998-07-30 2005-11-15 Wyeth Corp Substituierte chinazoline derivate
WO2000009481A1 (fr) 1998-08-11 2000-02-24 Takeda Chemical Industries, Ltd. Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
EP1162974A1 (en) 1999-03-19 2001-12-19 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
EP1182195A4 (en) 1999-05-07 2003-03-26 Takeda Chemical Industries Ltd CYCLIC CONNECTIONS AND APPLICATIONS THEREOF
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
UA71976C2 (en) * 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
JP2003504360A (ja) 1999-07-07 2003-02-04 アストラゼネカ ユーケイ リミテッド キナゾリン誘導体
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
NZ517120A (en) 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
CA2392554A1 (en) 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
EP1274692B1 (en) 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
WO2001087293A1 (fr) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Inhibiteurs de la ?-secretase
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK2142003A3 (en) 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
DE10042062A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042060A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1320529B1 (en) 2000-09-21 2006-05-24 Smithkline Beecham Plc Quinoline derivatives as antibacterials
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
IL155202A0 (en) 2000-10-20 2003-11-23 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
HUP0400683A2 (hu) * 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
KR100861486B1 (ko) 2001-02-21 2008-10-02 미쓰비시 타나베 파마 코퍼레이션 퀴나졸린 유도체
US7217716B2 (en) 2001-02-23 2007-05-15 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
AR033765A1 (es) 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
WO2002094790A1 (fr) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
MXPA04004219A (es) 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
HUP0501069A2 (en) 2001-12-12 2006-06-28 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
JP2003246780A (ja) 2001-12-17 2003-09-02 Eisai Co Ltd 含窒素芳香環化合物の製造方法
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
AU2003207291A1 (en) * 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
AU2003226705B2 (en) * 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
AU2003241898A1 (en) * 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
CN1192564C (zh) * 2002-06-06 2005-03-09 华为技术有限公司 开放最短路径优先协议第五类链路状态通告分组刷新的方法
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
AT6168U1 (de) * 2002-07-15 2003-05-26 Blum Gmbh Julius Scharnier
CA2677430C (en) 2002-08-19 2014-02-18 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
US20060167026A1 (en) * 2003-01-06 2006-07-27 Hiroyuki Nawa Antipsychotic molecular-targeting epithelial growth factor receptor
DE10300097A1 (de) * 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
DE10300098A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
CN1882573A (zh) 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
WO2005028470A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
DK1667992T3 (da) * 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
BRPI0414735A (pt) * 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
MX2008001609A (es) * 2005-08-04 2008-02-19 Novartis Ag Sales de vildagliptina.
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
KR20080028813A (ko) * 2006-09-27 2008-04-01 삼성전자주식회사 통신 시스템에서 파일럿 채널 탐색 제어 장치 및 방법

Also Published As

Publication number Publication date
EA019183B1 (ru) 2014-01-30
HN2010002408A (es) 2013-05-06
AU2009247782C1 (en) 2013-09-19
ES2444128T3 (es) 2014-02-24
CR11791A (es) 2011-01-12
EA201001773A1 (ru) 2011-06-30
AU2009247782A1 (en) 2009-11-19
TWI443095B (zh) 2014-07-01
US8404839B2 (en) 2013-03-26
EP2303276B1 (en) 2013-11-13
ZA201008283B (en) 2011-08-31
ECSP10010610A (es) 2010-12-30
TW201008923A (en) 2010-03-01
AR071714A1 (es) 2010-07-07
NI201000197A (es) 2012-11-07
AU2009247782B2 (en) 2012-06-28
BRPI0912170A2 (pt) 2015-10-13
NZ589883A (en) 2012-06-29
IL209199A0 (en) 2011-01-31
MX2010012442A (es) 2011-10-11
KR20110014192A (ko) 2011-02-10
DOP2010000346A (es) 2011-01-15
UY31820A (es) 2010-01-05
HK1152867A1 (en) 2012-03-16
CN102088979A (zh) 2011-06-08
WO2009138781A1 (en) 2009-11-19
US20090286982A1 (en) 2009-11-19
CA2723989C (en) 2017-04-25
JP2011520857A (ja) 2011-07-21
CU23927B1 (es) 2013-07-31
SA109300290B1 (ar) 2013-05-18
PE20091970A1 (es) 2010-02-05
MY183041A (en) 2021-02-08
CU20100222A7 (es) 2011-11-15
US20120035363A1 (en) 2012-02-09
US8088782B2 (en) 2012-01-03
CA2723989A1 (en) 2009-11-19
EP2303276A1 (en) 2011-04-06
SV2010003734A (es) 2011-03-15
CN102088979B (zh) 2013-10-16
CO6321256A2 (es) 2011-09-20
JP5739802B2 (ja) 2015-06-24

Similar Documents

Publication Publication Date Title
CL2009001159A1 (es) Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi]quinazolina; forma cristalina a del difumarato; procesos de preparacion; composicion faramceutica; y uso para tratar cancer de mama, gastrico, colorrectal, de cabeza y cuello, de ovario y de pulmon.
CL2014000930A1 (es) Dispersion solida que comprende n4-(4-([1,2,4]triazolo-[1,5-a]piridina-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina y un polimero de dispersion; proceso de preparacion; composicion farmaceutica; uso en el tratamiento del cancer de mama, gastrico, colorectal, pancreatico, entre otros.
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CL2012001480A1 (es) Sal cristalina anhidra del acido monofosforico de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea, forma a y b; metodo de preparacion; composicion farmaceutica; y su uso en el tratamiento de carcinomas, psoriasis, entre otras.
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
MX2010009156A (es) Terapia de combinacion 238.
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
CR20120213A (es) Métodos para el tratamiento del cáncer usando antagonistas de notch
BR112013027356A2 (pt) composição compreendendo aflibercept, ácido folínico, 5-fluorouacila (5-fu) e irinocetano (folfiri)
SV2012004192A (es) Nuevo uso antitumoral de cabazitaxel
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
WO2012087257A3 (en) Oral dosage form comprising imatinib and production of said oral dosage form
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TN2011000428A1 (en) Uses of nk receptor antagonists
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
PH12015500399A1 (en) Azaindolines
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX2011011177A (es) Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.
MX2011006532A (es) Compuestos anticancerigenos.